Radiopharm CFO initial insider holdings disclosed

Radiopharm Theranostics Ltd filed an initial Form 3 for Chief Financial Officer Aaron James Laurita, establishing his existing equity position.

Rhea-AI Filing Summary

Radiopharm Theranostics Ltd filed an initial Form 3 for Chief Financial Officer Aaron James Laurita, establishing his existing equity position. He directly holds 26,357 Ordinary Shares and an option to buy 17,857 Ordinary Shares at an exercise price of $0.2000 per share, expiring on November 30, 2026. The filing records holdings rather than new share purchases or sales.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Laurita Aaron James

Role Chief Financial Officer

Type	Security	Shares	Price	Value
holding	Option (right to buy)	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Option (right to buy) — 17,857 contracts (Direct); Ordinary Shares — 26,357 shares (Direct)

Key Figures

Direct Ordinary Shares held: 26,357 shares Options underlying shares: 17,857 shares Option exercise price: $0.2000 per share +2 more

5 metrics

Direct Ordinary Shares held 26,357 shares Total Ordinary Shares directly owned by CFO after reported holdings

Options underlying shares 17,857 shares Ordinary Shares underlying reported option (right to buy)

Option exercise price $0.2000 per share Exercise price for the option over 17,857 Ordinary Shares

Option expiration date November 30, 2026 Expiration date of CFO’s reported option position

Holding entries 2 entries Number of holding records (Ordinary Shares and option) in Form 3

Key Terms

Form 3, Ordinary Shares, Option (right to buy), exercise price

4 terms

Form 3 regulatory

"Radiopharm Theranostics Ltd filed an initial Form 3 for Chief Financial Officer"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Ordinary Shares financial

"He directly holds 26,357 Ordinary Shares and an option to buy"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Option (right to buy) financial

"The CFO holds an Option (right to buy) covering 17,857 Ordinary Shares"

exercise price financial

"an option to buy 17,857 Ordinary Shares at an exercise price of $0.2000 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Radiopharm Theranostics (RADX) Form 3 filing show for the CFO?

The Form 3 shows CFO Aaron James Laurita’s existing equity holdings. He directly owns 26,357 Ordinary Shares and holds options over 17,857 Ordinary Shares at a set exercise price, providing a baseline of his ownership when he became an insider.

How many Radiopharm Theranostics (RADX) shares does the CFO directly hold?

The CFO directly holds 26,357 Ordinary Shares of Radiopharm Theranostics Ltd. This figure reflects his ownership position reported on the Form 3 and does not, by itself, indicate any recent purchase or sale activity.

What stock options are reported for the Radiopharm Theranostics (RADX) CFO on Form 3?

The CFO holds an Option (right to buy) covering 17,857 Ordinary Shares with an exercise price of $0.2000 per share. These options are scheduled to expire on November 30, 2026, defining a time-limited opportunity to acquire additional shares.

Does the Radiopharm Theranostics (RADX) Form 3 reflect any insider buying or selling?

The Form 3 records holdings only, with transaction codes and directions classified as unknown and no buy or sell counts. It establishes the CFO’s starting share and option positions rather than documenting new market transactions.

Why is a Form 3 important for Radiopharm Theranostics (RADX) investors?

Form 3 is the initial ownership report for a company insider. It discloses how many shares and derivative securities, such as options, the insider holds at the outset, helping investors understand existing alignment between management and shareholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/30/2026 - 09:51 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Laurita Aaron James

(Last) (First) (Middle)

SUITE 1 LEVEL 3

62 LYGON STREET

(Street)

CARLTON SOUTH, VICTORIA 3053

(City) (State) (Zip)

AUSTRALIA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Radiopharm Theranostics Ltd [ RADX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	26,357	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	11/25/2022	11/30/2026	Ordinary Shares	17,857	$0.2	D

Explanation of Responses:

Remarks:

All exercise prices are in Australian dollars.

	/s/ Aaron James Laurita	04/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)